

COVID-19 Results Briefing

The United States of America

February 24, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the United States of America. The model was run on February 24, 2021 with data through February 22, 2021.

Despite increasing mobility and the spread of new variants, particularly B.1.1.7, daily cases continue a dramatic decline that began in the second week of January. While the decrease is likely driven by declining seasonality and rising vaccination, it is faster than expected. Daily deaths are also declining, but the decline is half the size of daily cases. The slower decline is due in part to the expected lag between the trend in cases and deaths, but may also be due to rising infection-fatality ratios in several states including Alabama, Arizona, California, Delaware, and Georgia. Mask use has fortunately remained high, with more than three-quarters of adults reporting they wear a mask when leaving home. As new variants likely spread, the behavioral response will be critical in determining if there will be an increase in cases and deaths in April and May. In our worse scenario, where mask use begins to decline this month, infections and detected cases may remain at current levels until late April. More rapid rebound mobility and faster reductions in mask use lead to scenarios with rising death rates in the spring. However, in our reference scenario, we expect continued reductions in daily deaths and cases through to the summer. Our forecasts still assume that past infection from any variant provides protection against new variants such as B.1.351 or P1. Given that there may be diminished or minimal cross-variant immunity, long-range forecasts may need to be revised upwards.

Current situation

- Daily reported cases in the last week decreased to 65,200 per day on average compared to 96,800 the week before (Figure 1). This represents a drop of nearly 70% in the last 5 weeks.
- Daily deaths in the last week decreased to 2,000 per day on average compared to 2,330 the week before (Figure 2). COVID-19 remains the number 1 cause of death in the United States of America this week (Table 1). Daily deaths have dropped nearly 35% in the last 5 weeks.
- The daily death rate is greater than 4 per million in 25 states (Figure 3).
- We estimated that 19% of people in the United States of America have been infected as of February 22 (Figure 4).
- Effective R, computed using cases, hospitalizations, and deaths, is less than 1 in all states (Figure 5).
- The infection-detection rate remains near 50% in the last week (Figure 6).

Trends in drivers of transmission

- A business curfew has been imposed in New York. Mandates have been lifted in Illinois, Massachusetts, Michigan, Montana, New York, Ohio, and Texas.
- Mobility last week continued to slowly rise, reaching to 28% below the pre-COVID-19 baseline (Figure 7). Mobility was near baseline (within 10%) in no states. Mobility was lower than 30% of baseline in 13 states.
- As of February 22, we estimated that 77% of people always wore a mask when leaving their home (Figure 9). Mask use is holding steady despite scaled-up vaccination. Mask use was lowest in Wyoming.
- There were 478 diagnostic tests per 100,000 people on February 22 (Figure 11).
- In the United States of America 73.7% of people say they would accept or would probably accept a vaccine for COVID-19. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 60% in Wyoming to 85% in Massachusetts (Figure 14).
- In our current reference scenario, we expect that 165.82 million will be vaccinated by June 1 (Figure 15).

Projections

- In our **reference scenario**, which represents what we think is most likely to happen, our model projects 574,000 cumulative deaths on June 1. This represents 76,000 additional deaths from February 22 to June 1 (Figure 16). Daily deaths are expected to decline steadily until June 1 (Figure 17).
- By June 1, we project that 88,600 lives will be saved by the projected vaccine rollout.
- If **universal mask coverage (95%)** were attained in the next week, our model projects 10,000 fewer cumulative deaths compared to the reference scenario on June 1 (Figure 16).
- Under our **worse scenario**, our model projects 601,000 cumulative deaths on June 1 (Figure 16). This represents 27,000 more deaths than in the reference scenario.
- Daily infections in the reference scenario should drop below 50,000 in mid-April and reach below 25,000 in late May. In the worse scenario, daily infections will remain above 100,000 until mid-May, and then slowly decline (Figure 18).
- Figure 19 compares our reference scenario forecasts to other publicly archived models. Los Alamos National Labs forecasts that daily deaths will begin to rise in the third week of March. All other models show continued declines through the end of their forecast periods.
- At some point from February through June 1, 17 states will have high or extreme stress on hospital beds (Figure 22). At some point from February through June 1, 18 states will have high or extreme stress on ICU capacity (Figure 21).

Model updates

In this week's model, we have made five updates. First, new blood bank seroprevalence data from South Africa has strengthened the evidence that the age-standardized infection-fatality ratio (IFR) is much lower in sub-Saharan Africa than previously estimated. Surveys in Kenya and Nigeria had supported this idea, but the more extensive data from South Africa have led us to revise the IFR for all countries in sub-Saharan Africa. This change revised upwards our estimates of the percentage of the population that has been infected in this region. Second, the third round Indian Council of Medical Research serosurvey found a higher level of seroprevalence at the national level than we have been estimating. In this week's analysis of past levels of infection, we have put more emphasis on this new round of survey data in estimating state-specific IFRs, which in turn is leading to higher estimates of cumulative infection. Third, the winter storm and electricity outages in Texas have had a noticeable impact on case, hospitalization, and death reporting. We have excluded data after the storm from the analysis. Fourth, we have continued to revise our variant scale-up estimates for the past and forecasts for future scale-up. For the past, for countries in Southern Africa without sufficient numbers of isolates sequenced, we have revised the likely start data for B.1.351 based on the scale-up of cases observed in these countries. A similar approach has been taken for Ghana. Newly available sequence data have led to revisions of the timing of the introduction of B.1.1.7, B.1.351, and P.1 in select locations. The maps below show our estimates of the prevalence of each variant this week by location. Fifth, we made two changes to the worse scenario. Rather than assuming immediate introduction of new variants B.1.351 or P.1 in all locations, we have assumed that the variant spreads to adjacent locations in 21 days, including across national borders. We have also assumed that mask use in those who have been vaccinated will begin declining one month after completed vaccination (rather than the reference scenario that assumes mask will begin declining three months after completed vaccination).





Figure 1. Reported daily COVID-19 cases

Table 1. Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

Cause name	Weekly deaths	Ranking
COVID-19	14,017	1
Ischemic heart disease	10,724	2
Tracheal, bronchus, and lung cancer	3,965	3
Chronic obstructive pulmonary disease	3,766	4
Stroke	3,643	5
Alzheimer's disease and other dementias	2,768	6
Chronic kidney disease	2,057	7
Colon and rectum cancer	1,616	8
Lower respiratory infections	1,575	9
Diabetes mellitus	1,495	10

Figure 2. Reported daily COVID-19 deaths




Figure 3. Daily COVID-19 death rate per 1 million on February 22, 2021




Figure 4. Estimated percent of the population infected with COVID-19 on February 22, 2021




Figure 5. Mean effective R on February 11, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.





Figure 6. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model.



*Due to measurement errors in cases and testing rates, the infection to detection rate (IDR) can exceed 100% at particular points in time.


Critical drivers

Table 2. Current mandate implementation



*Not all locations are measured at the subnational level.

Figure 7. Trend in mobility as measured through smartphone app use compared to January 2020 baseline



— France — Sweden — Canada
 — Italy — United Kingdom — United States of America

Figure 8. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on February 22, 2021




Figure 9. Trend in the proportion of the population reporting always wearing a mask when leaving home




Figure 10. Proportion of the population reporting always wearing a mask when leaving home on February 22, 2021




Figure 11. Trend in COVID-19 diagnostic tests per 100,000 people




Figure 12. COVID-19 diagnostic tests per 100,000 people on February 01, 2021




Figure 13. Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020




Figure 14. This figure shows the estimated proportion of the adult (18+) population that is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).





Figure 15. The number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.



Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the UK.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The **worse scenario** modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P1 begin to spread within 3 weeks in adjacent locations that do not already have B.1.351 or P1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The **universal masks scenario** makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.



Figure 16. Cumulative COVID-19 deaths until June 01, 2021 for three scenarios

Figure 17. Daily COVID-19 deaths until June 01, 2021 for three scenarios


Figure 18. Daily COVID-19 infections until June 01, 2021 for three scenarios




Figure 19. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi; <https://www.covidanalytics.io/home>), Imperial College London (Imperial; <https://www.covidsim.org>), The Los Alamos National Laboratory (LANL; <https://covid-19.bsvgateway.org/>), and the SI-KJalpha model from the University of Southern California (SIKJalpha; <https://github.com/scc-usc/ReCOVER-COVID-19>). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.




Figure 20. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered *low stress*, 5-9% is considered *moderate stress*, 10-19% is considered *high stress*, and greater than 20% is considered *extreme stress*.





Figure 21. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered *low stress*, 10-29% is considered *moderate stress*, 30-59% is considered *high stress*, and greater than 60% is considered *extreme stress*.



More information

Data sources:

Mask use data sources include PREMISE; Facebook Global symptom survey (This research is based on survey results from University of Maryland Social Data Science Center) and the Facebook United States symptom survey (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; YouGov COVID-19 Behaviour Tracker survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (<https://covidsurvey.mit.edu/>).

Data on vaccine candidates, stages of development, manufacturing capacity, and pre-purchasing agreements are primarily from Linksbridge and supplemented by Duke University.

A note of thanks:

We wish to warmly acknowledge the support of [these](#) and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit <http://www.healthdata.org/covid>.

Questions? Requests? Feedback? Please contact us at <https://www.healthdata.org/covid/contact-us>.